# Low-Dose Dobutamine and Single-Dose Tocilizumab in Acute Myocardial Infarction With High Risk of Cardiogenic Shock

Study · id `cardio:ct-nct05350592` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05350592](<https://clinicaltrials.gov/study/NCT05350592>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05350592

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 100 participants.

## Technical summary

Registry record NCT05350592. Randomized; quadruple masking; primary purpose treatment. Start 2022-03-13 (actual); primary completion 2025-06-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 100 participants (enrolled count; ClinicalTrials.gov record NCT05350592, source copy `cardio:ctgov-nct05350592-2025-07-17`, retrieved 2026-10-31)
- Started: 2022-03-13 (actual) (ClinicalTrials.gov record NCT05350592, source copy `cardio:ctgov-nct05350592-2025-07-17`, retrieved 2026-10-31)
- Primary completion: 2025-06-30 (actual) (ClinicalTrials.gov record NCT05350592, source copy `cardio:ctgov-nct05350592-2025-07-17`, retrieved 2026-10-31)
- Completion: 2025-09-30 (anticipated) (ClinicalTrials.gov record NCT05350592, source copy `cardio:ctgov-nct05350592-2025-07-17`, retrieved 2026-10-31)
- Countries: Denmark (ClinicalTrials.gov record NCT05350592, source copy `cardio:ctgov-nct05350592-2025-07-17`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05350592-2025-07-17`, retrieved 2026-10-31)

## The registry's words

- Brief title: Low-Dose Dobutamine and Single-Dose Tocilizumab in Acute Myocardial Infarction With High Risk of Cardiogenic Shock
- Acronym: DOBERMANN
- Condition: Acute Myocardial Infarction
- Condition: Cardiogenic Shock
- Intervention (Drug): Tocilizumab
- Intervention (Drug): Dobutamine
- Intervention (Drug): NaCl 0.9%
- Lead sponsor: Copenhagen University Hospital, Rigshospitalet
- Lead sponsor class: OTHER
- Collaborator: Novo Nordisk A/S
- Collaborator class: INDUSTRY
- Collaborator: Simon Spies Fonden
- Collaborator class: UNKNOWN
- Collaborator: Helge Peetz og Verner Peetz og hustru Vilma Peetz Legat
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Cardiogenic shock (`cardio:cardiogenic-shock`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry intervention name matches this record: Dobutamine (`cardio:dobutamine`)
- Registry lists this organization as the lead sponsor: Copenhagen University Hospital, Rigshospitalet (`cardio:org-copenhagen-university-hospital-rigshospitalet`)
- Registry lists this organization as a collaborator: Novo Nordisk (`cardio:novo-nordisk`)

## Provenance

Content hash: a18f5aa94e68d91fe1324179989f9ea77d33c105a9d48e83988f3e22d0f569ce
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
